Aristada Initio injection consists of a single dose given intramuscularly. Here is how it is usually employed:
- Loading Dose: Patient is given Aristada Initio injection in the gluteal or deltoid muscle depending on the physician’s instruction. Aristada Initio dose is usually 1050 mg.
- Reloading Injection: After Aristada Initiation injection, the patient may be administered a lower dose of Aristada (mostly 441 mg or 662 mg) between a span of 4 to 10 days to maintain adequate levels of the medication in circulation.
- Maintenance Dosing: After the first two injections, the patient will keep on receiving Aristada injections every month or every four to six weeks depending on the therapeutic dose prescribed. The therapeutic doses usually vary from 441 mg to up to 882 mg of Aristada
- Switching from Oral Aripiprazole to Aristada Initio: In a situation where a patient is switching from oral aripiprazole to Aristada Initio, Aristada Initio may be given first to rapidly bring about symptomatic control followed by the regular Aristada injections.
5. Return Visit: The patient should come back to the clinic after a while for maintenance injection and for the evaluation of the treatment. Treatment side effects and efficacy of treatment need to be monitored within acceptable limits.
The formulation of Aristada Initio consists primarily of Aripiprazole Lauroxil, the prodrug of Aripiprazole.
The prodrug treatment is an injectable antipsychotic medication that after injection is converted within the body into the active compound abripiprazole, an atypical antipsychotic agent which modulates the functions of specific neurotransmitters (primarily dopamine and serotonin) in the brain.
- Dopamine Modulation: D2 dopamine receptors are targeted by Aripiprazole, which is a partial agonist of this receptor. Therefore, it can activate the D2 receptors and at the same time block it depending on the dopaminergic tone.
This mechanism facilitates normalization of the dopaminergic dysregulation that causes positive symptoms of schizophrenia such as hallucinations, delusions, and disorganized thought patterns.
- Serotonin Modulation: It equally has an effect on serotonin receptors such as 5-HT1A (partial agonist) and 5-HT2A (antagonist of) where these promote a mood enhancing effect, anti-anxiety effect and improve cognitive functioning.
As such, Aristada Initio facilitates administration of Aripiprazole directly into systemic circulation, thereby leading to faster stabilization of the clinical symptoms than history oral medications which take their effect more gradually.
Aristada Initio is a medication which is effective and causes no or very little discomfort to the patient. However, like every other antipsychotic medication, it has some side effects as well.
These include
Common Side Effects:
- Reactions at the Cause of Injection (pain, swelling, or redness)
- Increased body mass
- Causing Drowsiness/Sedating
- Pain located in the Head
- A state of Psychomotor Agitation (the inability to sit still as if the patient is internally restless)
- Feeling faint or light-headed
- Queasiness
Before starting Aristada Initio treatment, it is essential that you inform your healthcare professional if any of the following applies to you:
- Pregnancy and lactation: Aristada is a medication in pregnancy category c. It takes second place if the benefits exceed the risks of its administration. The effect of aripiprazole on breast milk is not known, so the use of this drug should be avoided or informed to the physician during breastfeeding.
- Major cardiovascular diseases: since patients with heart disease, hypertension, and other major vascular disorders are at a higher risk of experiencing side effects, then the physician should use this medication carefully.
- History of or kidney damage liver: since Aripiprazole undergoes liver metabolism, it may be necessary to lower the dosage or heighten the supervision of patients with liver issues.
- Neuroleptic Malignant Syndrome (NMS): a serious illness that can be fatal. If you experience any symptoms including a high temperature, muscle stiffness or any form of confusion, please contact your doctor immediately.
- Diabetes or metabolic changes: Aristada may lead to increased blood sugar and cholesterol levels hence patients with diabetes or a history of diabetes in the family should be observed very carefully.
•Aged patients: treatment with Aristada is more dangerous in this group of elderly that suffer from dementia-related psychosis, thus they should not be treated with this medication since it increases the risk of stroke/death.
Inhibitors of CYP3A4 (ketoconazole, clarithromycin) could increase Aripiprazole levels, potentially resulting in a dose reduction.
The CYP2D6 inhibitors (fluoxetine, paroxetine) could increase Aripiprazole plasma levels, and potentially require dosage adjustments.
The CYP3A4 inducers (carbamazepine, rifampin) could decrease Aristada Initio levels; this may lead to its reduced effectiveness, thus its dose should be increased.
CNS Depressants:
Concomitant administration with CNS depressants (such as alcohol, benzodiazepines, and opioids) may lead to an increased sedation or depression of the CNS. Concomitant use should be exercised with caution.
Combining Aristada Initio with other antipsychotics or dopamine antagonists may increase the risk for EPS, sedation, or NMS.
Neuroleptic Malignant Syndrome (NMS):
As is the case with other antipsychotics, Aristada Initio carries a risk for NMS. Combining this drug with other dopamine antagonists may increase that risk. Such interactions will need to be closely followed in the course of treatment; more so, in a patient who changes from taking oral to injectable preparations of Aripiprazole.
- Aristada Initio (1050 mg) is usually given in a single high-dose injection for the purpose of initiation
. • Maintenance doses of Aristada 441 mg, 662 mg, or 882 mg are normally used monthly or every 4 to 6 weeks as per the treatment response and dose selected for the patient.
The Aristada Initio injection affords the rapid onset action that is needed to stabilize the patient prior to commencement of long acting maintenance dosing.
Aristada Initio is a prescription medication. It can only be prescribed by a qualified medical practitioner based on their evaluation of the patient’s condition and exercise of clinical judgment on the appropriateness of such treatment.
Such injection will be given to the patient by a healthcare professional.